open access

Vol 13, No 1 (2017)
Case report
Published online: 2017-07-21
Get Citation

Do we apply a personalised lung cancer therapy? Use of molecular tests in scheduling a multilineage treatment in a patient with lung adenocarcinoma

Marcin Nicoś, Paweł Krawczyk, Michał Szczyrek, Sławomir Mandziuk, Bożena Jarosz, Kamila Wojas-Krawczyk, Tomasz Kucharczyk, Katarzyna Reszka, Janusz Milanowski
DOI: 10.5603/OCP.2017.0004
·
Oncol Clin Pract 2017;13(1):24-29.

open access

Vol 13, No 1 (2017)
CASE REPORT
Published online: 2017-07-21

Abstract

Molecularly targeted therapies, which can be used in genetically selected patients, play an increasing role in the multidisciplinary approach to the treatment of lung cancer. Treatment personalisation extends the scope of therapy, prolongs survival of patients and decreases the risk of life-threatening side effects. In this report, we present the diagnostic and therapeutic history of a 57-year-old male with lung adenocarcinoma and activating EGFR gene mutation. The whole therapeutic approach involved a diagnostic segmentectomy, cytoreductive surgery of the primary tumour, and a palliative hemipelvectomy of metastases in the right hip joint followed by adjuvant radiotherapy as well as six lines of systemic treatment based on standard cytostatics and novel personalised agents. Regardless of a patient’s good performance status and relatively good tolerance of the treatment, futile continuation of the therapy despite the lack of a longer stabilisation of the disease remains questionable.

Abstract

Molecularly targeted therapies, which can be used in genetically selected patients, play an increasing role in the multidisciplinary approach to the treatment of lung cancer. Treatment personalisation extends the scope of therapy, prolongs survival of patients and decreases the risk of life-threatening side effects. In this report, we present the diagnostic and therapeutic history of a 57-year-old male with lung adenocarcinoma and activating EGFR gene mutation. The whole therapeutic approach involved a diagnostic segmentectomy, cytoreductive surgery of the primary tumour, and a palliative hemipelvectomy of metastases in the right hip joint followed by adjuvant radiotherapy as well as six lines of systemic treatment based on standard cytostatics and novel personalised agents. Regardless of a patient’s good performance status and relatively good tolerance of the treatment, futile continuation of the therapy despite the lack of a longer stabilisation of the disease remains questionable.

Get Citation

Keywords

lung adenocarcinoma, chemotherapy, molecularly targeted therapy, immunotherapy

About this article
Title

Do we apply a personalised lung cancer therapy? Use of molecular tests in scheduling a multilineage treatment in a patient with lung adenocarcinoma

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 1 (2017)

Article type

Case report

Pages

24-29

Published online

2017-07-21

DOI

10.5603/OCP.2017.0004

Bibliographic record

Oncol Clin Pract 2017;13(1):24-29.

Keywords

lung adenocarcinoma
chemotherapy
molecularly targeted therapy
immunotherapy

Authors

Marcin Nicoś
Paweł Krawczyk
Michał Szczyrek
Sławomir Mandziuk
Bożena Jarosz
Kamila Wojas-Krawczyk
Tomasz Kucharczyk
Katarzyna Reszka
Janusz Milanowski

References (25)
  1. Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5–29.
  2. Krajowy Rejestr Nowotworów: Nowotwory złośliwe opłucnej i płuca (C33-34) 2010. http://onkologia org pl/ (23.03.2017).
  3. Luo L, Hu Q, Jiang Jx, et al. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis. Asia Pac J Clin Oncol. 2015; 11(3): 253–261.
  4. Gadgeel SM, Gadgeel SM, Bepler G, et al. Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat. 2010; 13(6): 196–204.
  5. Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014; 15(4): 658–669.
  6. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer – ESMO clinical practice guidelines. Ann Oncol. 2016; 27(suppl 5): v1–v27.
  7. Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16(2): 141–151.
  8. Yatabe Y, Pao W, Jett JR. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol. 2012; 7(5): 775–776.
  9. Sharma A, Tan TH, Cheetham G, et al. Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases. J Thorac Oncol. 2012; 7(5): 941–942.
  10. Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014; 25(1): 126–131.
  11. De Waele M, Van Schil P. Limited resections in high-risk patients. Curr Opin Pulm Med. 2015; 21(4): 309–313.
  12. Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016; 9: 34.
  13. Park S, Keam B, Kim SeH, et al. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. Cancer Res Treat. 2015; 47(4): 630–637.
  14. Fossella FV. Docetaxel in second-line treatment of non-small-cell lung cancer. Clin Lung Cancer. ; 2002(Suppl 2): S23–28.
  15. Hata A, Katakami N, Yoshioka HI, et al. Yoshioka H. Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: comparison between T790M mutation-positive and -negative populations. J Clin Oncol. 2012; 30 (suppl): abstr. ; 7528.
  16. Wu WS, Chen YM. Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. J Pers Med. 2014; 4(3): 297–310.
  17. Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013; 14(8): 777–786.
  18. Reck M, Kaiser R, Mellemgaard A, et al. LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2): 143–155.
  19. Corrales L, Nogueira A, Passiglia F, et al. Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Front Med (Lausanne). 2017; 4: 13.
  20. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2015; 33(18_suppl): LBA109–LBA109.
  21. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387(10027): 1540–1550.
  22. Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255–265.
  23. Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Crit Rev Oncol Hematol. 2016; 101: 75–85.
  24. Yang JH, Ahn MJ, Kim DW, et al. Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017; 35(12): 1288–1296.
  25. Sueoka-Aragane N, Katakami N, Satouchi M, et al. MonitoringEGFRT790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Science. 2016; 107(2): 162–167.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl